Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: A controlled cardiac magnetic resonance imaging study

Karim Sacré, Benoit Brihaye, Fabien Hyafil, Jean Michel Serfaty, Brigitte Escoubet, Maria Christina Zennaro, Olivier Lidove, Jean Pierre Laissy, Thomas Papo

Research output: Contribution to journalArticle

Abstract

Objective. Antiphospholipid syndrome (APS) may cause coronary thrombosis. This study was undertaken to determine the prevalence of silent myocardial disease in patients with APS, using late gadolinium enhancement (LGE) of cardiac magnetic resonance imaging (CMRI). Methods. Twenty-seven consecutive patients with APS and 81 control subjects without known cardiovascular disease underwent CMRI. The prevalence of occult myocardial ischemic disease, as revealed by LGE, was compared between patients with APS and controls, and factors associated with myocardial disease were identified in patients with APS. Results. Myocardial ischemic disease, as characterized by LGE on CMRI, was present in 8 (29.6%) of 27 patients with APS, and imaging with LGE showed a typical pattern of myocardial infarction (MI) in 3 patients (11.1%). The myocardial scarring revealed on CMRI was not detected by electrocardiography or echocardiography. Although both patients with APS and control subjects shared a low risk of cardiovascular events, as calculated with the Framingham risk equation (mean ± SD 5.1 ± 8.2% and 6.5 ± 7.6%, respectively, for the absolute risk within the next 10 years; P = 0.932), the prevalence of myocardial ischemia was more than 7 times higher in patients with APS (P = 0.0006 versus controls). No association was found between myocardial disease in patients with APS and classic coronary risk factors. The presence of myocardial scarring tended to be more closely associated with specific features of APS, such as duration of the disease, presence of livedo, and positivity for anti-β2-glycoprotein I antibodies. Conclusion. The finding of a significant and unexpectedly high prevalence of occult myocardial scarring in patients with APS indicates the usefulness of CMRI with LGE for the identification of silent myocardial disease in such patients.

Original languageEnglish (US)
Pages (from-to)2093-2100
Number of pages8
JournalArthritis and Rheumatism
Volume62
Issue number7
DOIs
StatePublished - Jul 2010
Externally publishedYes

Fingerprint

Antiphospholipid Syndrome
Cardiomyopathies
Magnetic Resonance Imaging
Gadolinium
Cicatrix
Coronary Thrombosis
Myocardial Ischemia
Echocardiography
Glycoproteins
Electrocardiography
Cardiovascular Diseases
Myocardial Infarction

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology
  • Pharmacology (medical)

Cite this

Sacré, K., Brihaye, B., Hyafil, F., Serfaty, J. M., Escoubet, B., Zennaro, M. C., ... Papo, T. (2010). Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: A controlled cardiac magnetic resonance imaging study. Arthritis and Rheumatism, 62(7), 2093-2100. https://doi.org/10.1002/art.27488

Asymptomatic myocardial ischemic disease in antiphospholipid syndrome : A controlled cardiac magnetic resonance imaging study. / Sacré, Karim; Brihaye, Benoit; Hyafil, Fabien; Serfaty, Jean Michel; Escoubet, Brigitte; Zennaro, Maria Christina; Lidove, Olivier; Laissy, Jean Pierre; Papo, Thomas.

In: Arthritis and Rheumatism, Vol. 62, No. 7, 07.2010, p. 2093-2100.

Research output: Contribution to journalArticle

Sacré, K, Brihaye, B, Hyafil, F, Serfaty, JM, Escoubet, B, Zennaro, MC, Lidove, O, Laissy, JP & Papo, T 2010, 'Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: A controlled cardiac magnetic resonance imaging study', Arthritis and Rheumatism, vol. 62, no. 7, pp. 2093-2100. https://doi.org/10.1002/art.27488
Sacré, Karim ; Brihaye, Benoit ; Hyafil, Fabien ; Serfaty, Jean Michel ; Escoubet, Brigitte ; Zennaro, Maria Christina ; Lidove, Olivier ; Laissy, Jean Pierre ; Papo, Thomas. / Asymptomatic myocardial ischemic disease in antiphospholipid syndrome : A controlled cardiac magnetic resonance imaging study. In: Arthritis and Rheumatism. 2010 ; Vol. 62, No. 7. pp. 2093-2100.
@article{c1ff3c1501f34ea89c99aa79458c439c,
title = "Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: A controlled cardiac magnetic resonance imaging study",
abstract = "Objective. Antiphospholipid syndrome (APS) may cause coronary thrombosis. This study was undertaken to determine the prevalence of silent myocardial disease in patients with APS, using late gadolinium enhancement (LGE) of cardiac magnetic resonance imaging (CMRI). Methods. Twenty-seven consecutive patients with APS and 81 control subjects without known cardiovascular disease underwent CMRI. The prevalence of occult myocardial ischemic disease, as revealed by LGE, was compared between patients with APS and controls, and factors associated with myocardial disease were identified in patients with APS. Results. Myocardial ischemic disease, as characterized by LGE on CMRI, was present in 8 (29.6{\%}) of 27 patients with APS, and imaging with LGE showed a typical pattern of myocardial infarction (MI) in 3 patients (11.1{\%}). The myocardial scarring revealed on CMRI was not detected by electrocardiography or echocardiography. Although both patients with APS and control subjects shared a low risk of cardiovascular events, as calculated with the Framingham risk equation (mean ± SD 5.1 ± 8.2{\%} and 6.5 ± 7.6{\%}, respectively, for the absolute risk within the next 10 years; P = 0.932), the prevalence of myocardial ischemia was more than 7 times higher in patients with APS (P = 0.0006 versus controls). No association was found between myocardial disease in patients with APS and classic coronary risk factors. The presence of myocardial scarring tended to be more closely associated with specific features of APS, such as duration of the disease, presence of livedo, and positivity for anti-β2-glycoprotein I antibodies. Conclusion. The finding of a significant and unexpectedly high prevalence of occult myocardial scarring in patients with APS indicates the usefulness of CMRI with LGE for the identification of silent myocardial disease in such patients.",
author = "Karim Sacr{\'e} and Benoit Brihaye and Fabien Hyafil and Serfaty, {Jean Michel} and Brigitte Escoubet and Zennaro, {Maria Christina} and Olivier Lidove and Laissy, {Jean Pierre} and Thomas Papo",
year = "2010",
month = "7",
doi = "10.1002/art.27488",
language = "English (US)",
volume = "62",
pages = "2093--2100",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Asymptomatic myocardial ischemic disease in antiphospholipid syndrome

T2 - A controlled cardiac magnetic resonance imaging study

AU - Sacré, Karim

AU - Brihaye, Benoit

AU - Hyafil, Fabien

AU - Serfaty, Jean Michel

AU - Escoubet, Brigitte

AU - Zennaro, Maria Christina

AU - Lidove, Olivier

AU - Laissy, Jean Pierre

AU - Papo, Thomas

PY - 2010/7

Y1 - 2010/7

N2 - Objective. Antiphospholipid syndrome (APS) may cause coronary thrombosis. This study was undertaken to determine the prevalence of silent myocardial disease in patients with APS, using late gadolinium enhancement (LGE) of cardiac magnetic resonance imaging (CMRI). Methods. Twenty-seven consecutive patients with APS and 81 control subjects without known cardiovascular disease underwent CMRI. The prevalence of occult myocardial ischemic disease, as revealed by LGE, was compared between patients with APS and controls, and factors associated with myocardial disease were identified in patients with APS. Results. Myocardial ischemic disease, as characterized by LGE on CMRI, was present in 8 (29.6%) of 27 patients with APS, and imaging with LGE showed a typical pattern of myocardial infarction (MI) in 3 patients (11.1%). The myocardial scarring revealed on CMRI was not detected by electrocardiography or echocardiography. Although both patients with APS and control subjects shared a low risk of cardiovascular events, as calculated with the Framingham risk equation (mean ± SD 5.1 ± 8.2% and 6.5 ± 7.6%, respectively, for the absolute risk within the next 10 years; P = 0.932), the prevalence of myocardial ischemia was more than 7 times higher in patients with APS (P = 0.0006 versus controls). No association was found between myocardial disease in patients with APS and classic coronary risk factors. The presence of myocardial scarring tended to be more closely associated with specific features of APS, such as duration of the disease, presence of livedo, and positivity for anti-β2-glycoprotein I antibodies. Conclusion. The finding of a significant and unexpectedly high prevalence of occult myocardial scarring in patients with APS indicates the usefulness of CMRI with LGE for the identification of silent myocardial disease in such patients.

AB - Objective. Antiphospholipid syndrome (APS) may cause coronary thrombosis. This study was undertaken to determine the prevalence of silent myocardial disease in patients with APS, using late gadolinium enhancement (LGE) of cardiac magnetic resonance imaging (CMRI). Methods. Twenty-seven consecutive patients with APS and 81 control subjects without known cardiovascular disease underwent CMRI. The prevalence of occult myocardial ischemic disease, as revealed by LGE, was compared between patients with APS and controls, and factors associated with myocardial disease were identified in patients with APS. Results. Myocardial ischemic disease, as characterized by LGE on CMRI, was present in 8 (29.6%) of 27 patients with APS, and imaging with LGE showed a typical pattern of myocardial infarction (MI) in 3 patients (11.1%). The myocardial scarring revealed on CMRI was not detected by electrocardiography or echocardiography. Although both patients with APS and control subjects shared a low risk of cardiovascular events, as calculated with the Framingham risk equation (mean ± SD 5.1 ± 8.2% and 6.5 ± 7.6%, respectively, for the absolute risk within the next 10 years; P = 0.932), the prevalence of myocardial ischemia was more than 7 times higher in patients with APS (P = 0.0006 versus controls). No association was found between myocardial disease in patients with APS and classic coronary risk factors. The presence of myocardial scarring tended to be more closely associated with specific features of APS, such as duration of the disease, presence of livedo, and positivity for anti-β2-glycoprotein I antibodies. Conclusion. The finding of a significant and unexpectedly high prevalence of occult myocardial scarring in patients with APS indicates the usefulness of CMRI with LGE for the identification of silent myocardial disease in such patients.

UR - http://www.scopus.com/inward/record.url?scp=77954238594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954238594&partnerID=8YFLogxK

U2 - 10.1002/art.27488

DO - 10.1002/art.27488

M3 - Article

C2 - 20506512

AN - SCOPUS:77954238594

VL - 62

SP - 2093

EP - 2100

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 7

ER -